Company
Shionogi
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
8
3 still marketed
Novel approvals
6
Approvals since 2021
2
Originals and new uses
Phase 3 trials
33
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Xocova approved NovelMay 29, 2026
- Radicava Ors approved Priority reviewOrphanMay 12, 2022
- Fetroja new use Priority reviewSep 25, 2020
- Fetroja approved NovelPriority reviewNov 14, 2019
- Radicava approved NovelOrphanMay 5, 2017
- Ulesfia approved NovelApr 9, 2009
- Doribax approved NovelOct 12, 2007
- Rybix Odt approved May 5, 2005
Drugs in development (3)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- BPN14770zatolmilastPhase 34 trials
Tetra Discovery Partners · Fragile X Syndrome, Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder
- RedasemtideRedasemtide trifluoroacetate, S-005151Phase 21 trial
Shionogi · Acute Ischemic Stroke
- SASS-001Phase 21 trial
Shionogi · Sleep Apnea
Recruiting Phase 3 trials
Largest first.
- A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe DiseasePivotal-lookingRecruiting
ShionogiIndustry
NCT07743580 · 2,000 participants (planned) · Start Sep 14, 2026 · Primary completion Jun 30, 2028
Drug: Secutrelvir; Placebo · For: SARS-CoV-2
Sites: Coral Gables, Florida; Hialeah, Florida; Miami, Florida · 52 sites in all
- Study of Secutrelvir in Participants With COVID-19Pivotal-lookingRecruiting
ShionogiIndustry
NCT07746544 · 1,200 participants (planned) · Start Aug 5, 2026 · Primary completion Jul 31, 2027
Drug: Secutrelvir; Placebo · For: COVID-19
Sites: Multiple Locations, Japan
Marketed drugs (3)
Newest FDA action first.
- Fetroja Cefiderocol Sulfate Tosylate · 2019
- Xocova Ensitrelvir · 2026
- Radicava Ors Edaravone · 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.